Acromegaly is a rare endocrine disorder, associated with significant morbidity and mortality due to the harmful effects of prolonged exposure to increased levels of growth hormone (GH) and its effector, insulin-like growth factor-1 (IGF-1). The most common cause of acromegaly is a pituitary adenoma, for which surgical resection is usually the first choice treatment. In cases where surgical resection is not possible, or where the patient declines surgery, somatostatin analogues (SSAs) are used as first-line medical therapy. Other therapeutic options include dopamine antagonists and the GH receptor antagonist -pegvisomant. In addition, considerable current research is investigating the clinical utility of combined therapies. Disease control is defined in terms of reduction of GH and IGF-1 normalisation and reduction in mortality levels to those seen in the general population. Reported disease control rates of acromegaly are highly variable and it has been reported that treatment efficacy in clinical practice is considerably lower than the success rates reported by reference centres. There is therefore a substantial need for improved disease management strategies for acromegaly.
More than 90 % of cases of acromegaly are caused by a benign GH-secreting adenoma in pituitary somatotroph cells. 16 The increases in morbidity and mortality associated with acromegaly result not only from oversecretion of GH and IGF-1 but also from the effect of the tumour mass.
GH induces the synthesis of peripheral IGF-1 which induces cell proliferation and inhibits apoptosis. 17 Somatostatin regulates the release of GH, and its biological action is mediated by five somatostatin receptors (SSTRs) . Approximately 90 % of GH-secreting pituitary adenomas express SSTR subtypes 2 and 5 (SSTR2 and SSTR5). 4 In the presence of somatostatin, these receptors signal the pituitary gland to suppress GH secretion.
Advances in understanding the cellular origin of pituitary tumours have led to significant improvements in approaches to the treatment of acromegaly, and tight biochemical control of the disease can reduce mortality levels to compare with those of the general population. 13 The aim of this article is to discuss the criteria for disease control, review studies detailing the efficacy of various therapeutic strategies in management of the disease and to highlight the fact that currently used pharmacological therapies may not be achieving adequate disease control.
Diagnosis
The onset of the symptoms in acromegaly is insidious and most signs are insufficiently characteristic to allow early diagnosis. However, early detection of the disease is crucial to prevent the development of irreversible complications, including cardiomyopathy, respiratory dysfunction and arthropathy. 8 Patients with an estimated disease duration of >10 years have a relative risk of cardiac complications three-times higher than patients with estimated disease duration ≤5
years. 18 Growth of acral parts, which may be observed as an increase in shoe or ring size, is often the reason for patients to seek medical advice. Diagnosis may begin with a clinical suspicion from a physician who is working in a field other than endocrinology. For example, a dentist may recognise a bite malocclusion typical of a patient with acromegaly whose lower jaw is protruding further than the upper jaw, or an ophthalmologist may find a visual field defect.
Biochemical analysis is usually necessary to confirm a diagnosis of acromegaly. Diagnosis is based on the finding of elevated IGF-1 levels, and a failure to suppress GH in response to an oral glucose tolerance test (OGTT). Unlike the general population, acromegaly patients do not suppress GH secretion in response to glucose. A post-OGTT GH level >0.4 μg/l is the most recently designated cut-off level used to diagnose acromegaly. 19 Serum prolactin should also be measured in all patients diagnosed as having acromegaly because prolactin cosecretion can identify a subset of patients at elevated risk of disease persistence after surgery. 20 Acromegaly causes typical changes of the face in the early stages of the disease, and recent research has suggested that face classification software may be able to identify subtle facial features indicative of the disease that are difficult to visually identify and may thus be a useful diagnostic tool.
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Measuring Disease Control in Acromegaly
The treatment goals for patients with acromegaly include:
• normalised IGF-1 levels;
• reduction of GH levels to <1 μg/l;
• removal or control of tumour mass;
• relief of signs and symptoms of the disease; and
• reduced mortality rates to those seen in the general population.
Treatment of acromegaly can also result in significant improvements in co-morbidities such as cardiovascular disease. 22 A consensus guideline on the criteria for the cure of acromegaly was published in 2010, and disease control is defined as:
• a random or mean GH level of <1 μg/l;
• a nadir GH level after OGTT of <0.4 μg/l; and
• achievement of age and sex normalised levels of IGF-1. A study found that overall IGF-1 levels (especially discordant levels)
19
are more predictive than GH in terms of insulin sensitivity, a common metabolic abnormality in active acromegaly, and clinical symptom score. 23 While elevations in GH generally correlate to elevations in IGF-1, discordance (elevated IGF-1 and normal GH, or elevated GH and normal IGF-1) has been reported in 9-39 % of patients receiving medical therapy for acromegaly, complicating treatment decisions.
Management of patients with discordant levels of IGF-1 and GH requires expertise and should be individualised. 24 Reported disease control rates of acromegaly are highly variable, 25 and this may be a result of differences between these studies in the criteria used to determine these rates that include:
• study design (prospective versus retrospective studies);
• patient population (selected or non-selected patients for response);
• expert centres involved; and
• the type of assays used to determine biochemical control. 19 In the course of the past decade, techniques used for measuring GH and IGF-1 have changed and immunoassays for GH have become considerably more sensitive. However, there is a lack of validation and standardisation data relating to the new assays, and a lack of uniformity in reference standards. 26 In addition, there can be daily fluctuations in GH levels, and normal levels are age and sex dependent. IGF-1 levels can also be influenced by age, gender, season, nutritional status and comorbidities. 26 A recent consensus statement concluded that considerable improvements are required in the areas of GH and IGF-1 assay performance and comparability, and it recommended that a commutable standard for each assay be implemented for worldwide use.
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A recent review suggested that the response to somatostatin analogues (SSAs) in acromegaly should be assessed by considering the biochemical effects and those on tumour mass because only the lack of both responses is indicative of a poor response or resistance.
The latter evidence occurs in less than 25 % of SSA-treated patients after 12 months. 
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Surgery is considered the most effective option to achieve rapid and complete cure and remains the most common first-line treatment, particularly in patients with enclosed adenomas, although the proportion of patients receiving primary medical therapy has risen in recent years (see Table 2 ). 30 Even if complete surgical resection cannot be achieved, the reduction in tumour mass resulting from debulking surgery can lead to a considerable reduction of symptoms and increases the likelihood of achieving biochemical disease control. 31 Most surgical procedures employ minimally invasive, endoscopic transsphenoidal techniques which can achieve biochemical response in approximately 40-60 % of patients.
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Medical therapy is indicated in patients who fail to achieve remission after surgery, in rare patients for whom surgery is contraindicated or in patients who are unlikely to achieve biochemical control with surgery.
It is also used following radiotherapy. 33 There are three classes of medical therapy: dopamine agonists (DAs), SSAs and a GH receptor antagonist -pegvisomant (see Table 3 ). All have shown varying degrees of efficacy in clinical trials (see Table 4 ).
DAs such as cabergoline are sometimes preferred by patients and physicians because they are inexpensive and administered orally.
However, they are effective only in a minority of patients -DA agonists alone showed a 13 % disease control rate in a Belgian registry study. 30 A recent meta-analysis (15 studies, 227 patients)
found that cabergoline monotherapy normalises IGF-1 levels in one-third of patients with acromegaly, though none of these studies were randomised or placebo-controlled. 61 and Manjila et al., 2010. 16 SSAs are the most widely used medical treatments for acromegaly and can achieve disease control after one month of treatment (see Figure 1 ). 35 The rationale behind their use is based on the inhibitory effects of native somatostatin on GH secretion. Initial formulations of the SSA octreotide were administered by subcutaneous (SC)
injections three times a day. A 1997 study showed that pre-treatment 33 A critical analysis found that all formulations had equivalent efficacy. 37 Predictors of response include gender, age, initial GH and IGF-1 levels, tumour mass and adequate expression of SSRT2 and SSRT5. 28 Treatment with OCT-LAR for 12 months has been found to reverse acromegalic cardiomyopathy in most young patients (age <40 years) with short disease duration and achieving disease control. 38 In another study, the majority of patients with acromegaly (75.5 %) had 25 % or greater tumour shrinkage after 12 months of primary treatment with SSAs. 39 Recent data suggest that first-line treatment with SSAs has equivalent efficacy to surgery, 40 and that SSAs are associated with improved cardiac outcomes. 41 Evidence indicates that pre-operative treatment with lanreotide or OCT-LAR results in a better post-operative outcome. 42, 43 SSAs have also demonstrated impressive long-term efficacy and safety as first-line therapy: SSA therapy for five years controlled GH in 100 % of cases and IGF-1 in 97.8 %, as well as resulting in tumour shrinkage by a median 80 %, and significant improvements in hypertension, cardiac performance and dyslipidemia. 41 The GH receptor antagonist pegvisomant has high efficacy but is the most expensive of the currently available medical therapies. A 52-week, multicentre, open-label, randomised study (n=118) concluded that pegvisomant and OCT-LAR were equally effective at normalising IGF-1 in the overall population, and pegvisomant was more effective in patients with higher baseline IGF-1 levels. Pegvisomant had a more favourable effect on parameters of glycaemic control. 44 In patients treated with pegvisomant for a year, IGF-1 levels were normalised in 97 % of patients following adequate dose titration. 45 Patients also reported improvements in signs and symptoms of acromegaly. A recent global safety surveillance study (n=1,288) of long-term treatment of acromegaly with pegvisomant concluded after five years of treatment, 63.2 % of subjects had normal IGF-1 levels at a mean dose of 18 mg/day. 46 The treatment was generally safe and well-tolerated. To be cost-effective, however, a UK study suggested that the price of pegvisomant should be reduced by one-third. 47 Cost savings may be achieved by the use of combination therapy, enabling lower drug doses. Several studies have demonstrated the efficacy of combination therapy in acromegaly. In a study of 10 patients with acromegaly who were poor responders to octreotide, treatment with the combination of lanreotide and cabergoline resulted in suppression of serum GH and normalisation of plasma IGF-1 levels in 40 and 50 % of patients, respectively, after three months. 48 In a recent study, co-administration of lanreotide Autogel and pegvisomant normalised IGF-1 levels in 57.8 % patients with acromegaly partially controlled by SSAs alone. 49 In one study the combination of monthly SSAs and weekly pegvisomant resulted in normalisation of levels in 18 of 19 (95 %) patients who completed 42 weeks of treatment. 50 Another study demonstrated that this combination resulted in significant improvements to patient QoL. 51 Long-term combined treatment with SSAs and twice-weekly pegvisomant has been shown to be safe up to more than four years. 52 A recent prospective clinical study suggested that combination treatment with cabergoline and pegvisomant is more effective at reducing IGF-1 levels than either cabergoline or pegvisomant monotherapy. 53 Additionally, pegvisomant is also useful to improve acromegaly co-morbidities. [54] [55] [56] [57] Acromegaly Consensus Group guidelines for the management of acromegaly suggest the use of DAs when the patient prefers oral medication or after surgery in selected patients, such as those with markedly elevated prolactin, or as additive therapy in patients with only a partial response to a maximum dose of SSAs. 17 SSAs are recommended as first-line therapy when there is a low probability of a surgical cure (for example, large extracellular tumours with no evidence of central compressive effects), after surgery has failed to achieve biochemical control and before surgery to improve severe co-morbidities that prevent or complicate immediate surgery. They are also recommended to provide partial biochemical disease control during the lag time between administration of radiation therapy and the onset of benefit. Pegvisomant is recommended in patients that have persistently elevated IGF-1 levels despite maximum doses of SSAs, and in combination with SSAs.
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Treatment Effectiveness in Clinical Practice
It has previously been reported that a biochemical response is achieved by approximately 70 % of patients receiving SSAs. However, the role of surgery in the management of acromegaly is still important and debulking surgery may result in improved outcomes in patients with a high GH concentration and a large tumour. 59 A review of data from registry studies shows that the majority of patients with acromegaly do not achieve disease control. 30, 32, 58 There remains a need for improved definition of disease control in acromegaly. Improvements in biochemical assay performance and comparability are also required, as is uniformity of reference 
